Tuesday, May 04, 2021

Avivagen Inc. (VIVXF)(VIV:CA)
Another Contract, This Time for 72 Tonnes

Avivagen Inc is a Canadian based company operating in the healthcare sector. It develops science-based, natural health products for animals. It develops and commercializes products for livestock feeds to replace antibiotics for growth promotion and to help prevent disease by supporting the animal’s own health defenses. Its product range includes OxC-beta, Vivamune health chews, Oximunol chewable tablets, and Carotenoid Oxidation products.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

New Order. Yesterday, Avivagen announced it entered into a contract for a four tonnes per month recurring order from Meyenberg International, the Company’s consultant in Mexico. The contract, which has a term of 18 months, includes an order for 500 kilograms delivered April 30th and a commitment to purchase a minimum of four tonnes per month, commencing July 2021 and ending October 2022. This contract should contribute some $2.4 million of revenue in 2021.


Order Momentum.  The Meyenberg order continues the order momentum for Avivagen, building off the April 26th announcement that Avivagen received a purchase order for a single shipment of 4.4 metric tonnes of OxC-beta Livestock, the largest single shipment purchase order of OxC-beta to date …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.